R
Rafael Rivas-Santisteban
Researcher at Carlos III Health Institute
Publications - 30
Citations - 481
Rafael Rivas-Santisteban is an academic researcher from Carlos III Health Institute. The author has contributed to research in topics: Receptor & Cannabinoid. The author has an hindex of 6, co-authored 26 publications receiving 203 citations. Previous affiliations of Rafael Rivas-Santisteban include University of Barcelona.
Papers
More filters
Journal ArticleDOI
Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1-CB2 Heteroreceptor Complexes.
Gemma Navarro,Gemma Navarro,Katia Varani,Irene Reyes-Resina,Irene Reyes-Resina,Verónica Sánchez de Medina,Rafael Rivas-Santisteban,Rafael Rivas-Santisteban,Carolina Sánchez-Carnerero Callado,Fabrizio Vincenzi,Salvatore Casano,Carlos Ferreiro-Vera,Enric I. Canela,Enric I. Canela,Pier Andrea Borea,Xavier Nadal,Rafael Franco,Rafael Franco +17 more
TL;DR: Investigation of the binding properties of CBG to cannabinoid CB1 (CB1R) and CB2 (CB2R) receptors and the effects of the compound on agonist activation of those receptors and of CB1–CB2 heteroreceptor complexes indicate that CBG is indeed effective as regulator of endocannabinoid signaling.
Journal ArticleDOI
Cannabidiol skews biased agonism at cannabinoid CB1 and CB2 receptors with smaller effect in CB1-CB2 heteroreceptor complexes.
Gemma Navarro,Irene Reyes-Resina,Rafael Rivas-Santisteban,Verónica Sánchez de Medina,Paula Morales,Salvatore Casano,Carlos Ferreiro-Vera,Alejandro Lillo,David Aguinaga,Nadine Jagerovic,Xavier Nadal,Rafael Franco,Rafael Franco +12 more
TL;DR: For the first time, GPCR biased agonism is characterized in an heteromeric context and was reduced when assays were performed in cells expressing the two receptors, thus suggesting that the heteromer allows less functional selectivity.
Journal ArticleDOI
Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB1, CB2 and CB1/CB2 heteromer receptors.
Gemma Navarro,Katia Varani,Alejandro Lillo,Fabrizio Vincenzi,Rafael Rivas-Santisteban,Iu Raïch,Irene Reyes-Resina,Carlos Ferreiro-Vera,Pier Andrea Borea,Verónica Sánchez de Medina,Xavier Nadal,Rafael Franco +11 more
TL;DR: Results here reported and the recent elucidation of the three-dimensional structure of CB1 and CB2 receptors help understanding the mechanism of action that might be protective and the molecular drug-receptor interactions underlying biased signaling.
Journal ArticleDOI
Adenosine A2A Receptor Antagonists Affects NMDA Glutamate Receptor Function. Potential to Address Neurodegeneration in Alzheimer's Disease.
Rafael Franco,Rafael Franco,Rafael Rivas-Santisteban,Rafael Rivas-Santisteban,Mireia Casanovas,Mireia Casanovas,Alejandro Lillo,Carlos A. Saura,Carlos A. Saura,Gemma Navarro,Gemma Navarro +10 more
TL;DR: A2AR antagonists such as istradefylline, which is already approved for Parkinson’s disease, have potential to afford neuroprotection in AD in a synergistic-like fashion, i.e., via both neurons and microglia.
Book ChapterDOI
Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer's, Parkinson's, and Huntington's Diseases.
TL;DR: This chapter focuses on the potential of cannabinoids to afford neuroprotection, i.e. avoid or retard neuronal death, and addresses the issue of proving neuroprotection in humans.